Please note that any funds granted from the FSHD Canada Foundation cannot be used to cover more than ten percent (10%) of overhead costs.
Identify Biomarkers for FSHD Using Omics Approaches
Investigator: Yi-Wen Chen, Ph.D. (Children’s Research Institute in Silver Spring, Maryland) Biomarkers are biological changes that can be used as indicators of physiological and disease states. Biomarkers can be valuable…
Read MoreStryka-001 treatment in the FSHD-like mouse model
Investigator: Dean Burkin, PhD, and Peter Jones, PhD (University of Nevada, Reno School of Medicine) This is a project to validate the efficacy of a potential drug therapy for FSHD…
Read MoreA Xenograft Model of FSHD for Testing Therapeutics
Investigator: Robert J Bloch PhD, Professor of Physiology at the University of Maryland Facioscapulohumeral muscular dystrophy (FSHD) affects 1 in approximately 15,000 individuals worldwide. One of the obstacles in developing treatments…
Read MoreDeveloping LNA-based therapy for FSHD
Investigators: • Yi-Wen Chen Children’s National Health System (Washington DC) • Toshifumi Yokota University of Alberta Faculty of Medicine and Dentistry (Alberta, Canada) Yi-Wen Chen and Toshifumi Yokota are investigating one…
Read MoreFacio Therapies
Facio Therapies (Facio-therapies.com) is a company based in the Netherlands that is focused on finding a cure for FSHD. Facio have screened over 34,000 small molecule compounds, and obtained over…
Read MoreFSHD myofibers cultured from human xenografts
FSH Muscular Dystrophy (FSHD) affects 1 in approximately 8,300 individuals worldwide. One of the obstacles in developing treatments for FSHD is the lack of a small animal model of the…
Read More